Could ozempic protect hearts in type 1 diabetes? new trial aims to find out
NCT ID NCT05819138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether semaglutide, a drug already used for type 2 diabetes and weight loss, can improve heart and kidney function in adults with type 1 diabetes. The study will measure artery stiffness, insulin sensitivity, and kidney blood flow in 60 participants over time. Semaglutide is not FDA-approved for this use, so the results will help determine if it could become a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Ozempic)
What this could lead to
If it works, this could point toward a new way to protect heart and kidney health in people with type 1 diabetes.
What could go wrong
This is a small, early-phase trial in type 1 diabetes, and semaglutide is not yet approved for this use. It may not show the same benefits seen in type 2 diabetes, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington Medicine Diabetes Institute (UWMDI)
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact